Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $125.00 at Citigroup

Apogee Therapeutics (NASDAQ:APGE) had its price objective hoisted by Citigroup from $95.00 to $125.00 in a research note released on Tuesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

A number of other brokerages have also recently commented on APGE. Stifel Nicolaus set a $133.00 price objective on Apogee Therapeutics in a research note on Tuesday, January 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $95.00 target price on shares of Apogee Therapeutics in a research report on Monday, February 2nd. Canaccord Genuity Group increased their target price on Apogee Therapeutics from $89.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday. Stephens initiated coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 16th. They issued an “overweight” rating and a $95.00 price target for the company. Finally, UBS Group upgraded shares of Apogee Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 7th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Apogee Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $110.43.

Apogee Therapeutics Trading Down 7.9%

Shares of NASDAQ APGE opened at $73.00 on Tuesday. The firm has a market capitalization of $5.07 billion, a P/E ratio of -17.30 and a beta of 1.39. The firm’s 50-day moving average price is $71.16 and its 200-day moving average price is $63.95. Apogee Therapeutics has a 1-year low of $26.20 and a 1-year high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.02. Equities research analysts forecast that Apogee Therapeutics will post -3.09 EPS for the current year.

Insiders Place Their Bets

In other Apogee Therapeutics news, Director Fairmount Funds Management Llc sold 1,750,000 shares of Apogee Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the transaction, the director owned 298,647 shares of the company’s stock, valued at $22,786,766.10. This trade represents a 85.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carl Dambkowski sold 18,700 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $77.84, for a total value of $1,455,608.00. Following the completion of the transaction, the insider owned 212,523 shares in the company, valued at $16,542,790.32. The trade was a 8.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,839,700 shares of company stock valued at $140,118,083 in the last 90 days. 42.77% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. purchased a new stake in shares of Apogee Therapeutics during the 4th quarter valued at $25,000. Los Angeles Capital Management LLC bought a new stake in shares of Apogee Therapeutics during the 4th quarter worth $37,000. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after buying an additional 246 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Apogee Therapeutics in the 4th quarter worth about $136,000. Finally, Ensign Peak Advisors Inc bought a new position in Apogee Therapeutics during the fourth quarter valued at about $170,000. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics News Roundup

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase 2 Part A data for zumilokibart (APG777) showed durable maintenance and deepening of responses with every‑3‑month and every‑6‑month dosing (e.g., 75% and 85% maintained EASI‑75), supporting the drug’s infrequent‑dosing value proposition. GlobeNewswire: 52‑Week Data
• Positive Sentiment: Analysts reacted quickly with multiple buy ratings and big price‑target increases (Guggenheim, Canaccord, Citi, BTIG), lifting sentiment that the program could support late‑stage development or M&A interest. Benzinga: Analyst Upgrades
• Positive Sentiment: Investor write‑ups and media coverage highlighted the favorable maintenance results and potential next catalysts (Part B induction data in Q2 and possible phase‑3 start in H2 2026), sustaining bullish narrative. Seeking Alpha: Strong Buy / Catalyst Summary
• Neutral Sentiment: Company held a conference call/webcast to review the Part A 52‑week data, providing more transparency on durability and safety that investors can digest for modeling. GlobeNewswire: Conference Call
• Neutral Sentiment: Short‑interest notices in the feed show zero reported short shares (likely a data artifact); they do not provide meaningful evidence of positioning pressure.
• Negative Sentiment: Apogee announced a proposed $300 million underwritten public offering (with up to $45M option), which raises dilution risk and often triggers selling pressure after a rally — the most likely proximate cause of the intraday pullback. GlobeNewswire: Offering Announcement

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.